PDF(Pubmed)
Abstract：
BACKGROUND: Hepatocellular carcinoma with peritoneal metastasis (HCC-PM) has a poor outlook. Traditional treatments have limited effect on survival. The safety and efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) have been shown in other peritoneal cancers. This study evaluates the role of CRS + HIPEC in HCC-PM.
METHODS: A retrospective analysis of HCC-PM patients treated with CRS + HIPEC at Beijing Shijitan Hospital from March 2017 to December 2023 was conducted, assessing clinical features, severe adverse events (SAEs), and overall survival (OS) rates.
RESULTS: The study population comprised 10 HCC-PM patients who underwent CRS + HIPEC. The median peritoneal cancer index (PCI) was 25, and complete cytoreduction (CC0 ~ 1) was achieved in half of the patients. Three patients experienced SAEs within 30 days postoperatively. The 1-year, 3-year, and 5-year OS rates were recorded as 89.0%, 89.0%, and 21.0% respectively, with a median OS1 of 107.8 months and OS2 of 49.9 months. The median progression-free survival (PFS) was 5.0 months.
CONCLUSIONS: The application of CRS + HIPEC offers significant benefits to patients with HCC-PM. A selected group of patients may achieve prolonged PFS. Incorporating CRS + HIPEC into the treatment paradigm can thus be considered a strategic therapeutic option for patients with HCC-PM.
METHODS: A retrospective analysis of HCC-PM patients treated with CRS + HIPEC at Beijing Shijitan Hospital from March 2017 to December 2023 was conducted, assessing clinical features, severe adverse events (SAEs), and overall survival (OS) rates.
RESULTS: The study population comprised 10 HCC-PM patients who underwent CRS + HIPEC. The median peritoneal cancer index (PCI) was 25, and complete cytoreduction (CC0 ~ 1) was achieved in half of the patients. Three patients experienced SAEs within 30 days postoperatively. The 1-year, 3-year, and 5-year OS rates were recorded as 89.0%, 89.0%, and 21.0% respectively, with a median OS1 of 107.8 months and OS2 of 49.9 months. The median progression-free survival (PFS) was 5.0 months.
CONCLUSIONS: The application of CRS + HIPEC offers significant benefits to patients with HCC-PM. A selected group of patients may achieve prolonged PFS. Incorporating CRS + HIPEC into the treatment paradigm can thus be considered a strategic therapeutic option for patients with HCC-PM.
摘要：
背景：伴有腹膜转移的肝细胞癌（HCC-PM）前景不佳。传统治疗对生存的影响有限。在其他腹膜癌中已经显示了细胞减灭术和腹腔热化疗（CRSHIPEC）的安全性和有效性。本研究评估了CRS+HIPEC在HCC-PM中的作用。
方法：回顾性分析2017年3月至2023年12月在北京世纪坛医院接受CRS+HIPEC治疗的HCC-PM患者，评估临床特征，严重不良事件（SAE），和总生存率（OS）。
结果：研究人群包括10名接受CRS+HIPEC的HCC-PM患者。中位腹膜癌指数(PCI)为25,半数患者达到完全细胞减灭术(CC0~1)。3例患者在术后30天内出现SAE。1年,3年,5年OS率为89.0%，89.0%,和21.0%，OS1中位数为107.8个月，OS2中位数为49.9个月。中位无进展生存期（PFS）为5.0个月。
结论：CRS+HIPEC的应用为HCC-PM患者提供了显著的益处。选定的一组患者可以达到延长的PFS。因此，将CRS+HIPEC纳入治疗范式可以被认为是HCC-PM患者的战略治疗选择。
方法：回顾性分析2017年3月至2023年12月在北京世纪坛医院接受CRS+HIPEC治疗的HCC-PM患者，评估临床特征，严重不良事件（SAE），和总生存率（OS）。
结果：研究人群包括10名接受CRS+HIPEC的HCC-PM患者。中位腹膜癌指数(PCI)为25,半数患者达到完全细胞减灭术(CC0~1)。3例患者在术后30天内出现SAE。1年,3年,5年OS率为89.0%，89.0%,和21.0%，OS1中位数为107.8个月，OS2中位数为49.9个月。中位无进展生存期（PFS）为5.0个月。
结论：CRS+HIPEC的应用为HCC-PM患者提供了显著的益处。选定的一组患者可以达到延长的PFS。因此，将CRS+HIPEC纳入治疗范式可以被认为是HCC-PM患者的战略治疗选择。
